{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:51:40Z","timestamp":1790880700739,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>AntiTNF-\u03b1 biosimilars are broadly available for the treatment of inflammatory arthritis. There are a lot of data concerning the maintenance of clinical efficacy after switching from originators to biosimilars; therefore, such a transition is increasingly encouraged both in the US and Europe. However, there are reports about flares and adverse events (AE) as a non-medical switch remains controversial due to ethical and clinical implications (efficacy, safety, tolerability). The aim of our work was to evaluate the disease activity trend after switching from etanercept originator (oETA-Enbrel) to its biosimilar (bETA-SP4\/Benepali) in a cohort of patients in Turin, Piedmont, Italy. In this area, the switch to biosimilars is stalwartly encouraged. We switched 87 patients who were in a clinical state of stability from oETA to bETA: 48 patients were affected by Rheumatoid Arthritis (RA),26 by Psoriatic Arthritis (PsA) and 13 by Ankylosing Spondylitis (AS).We evaluated VAS-pain, Global-Health, CRP, number of swollen and tender joints, Disease Activity Score on 28 joints (DAS28) for RA, Disease Activity in Psoriatic Arthritis (DAPSA) for PsA, Health Assessment Questionnaire (HAQ) and Health Assessment Questionnaire for the spondyloarthropathies (HAQ-S),Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for AS patients. 11\/85 patients (12.6%) stopped treatment after switching to biosimilar etanercept. No difference was found between oETA and bETA in terms of efficacy. However, some arthritis flare and AE were reported. Our data regarding maintenance of efficacy and percentage of discontinuation were in line with the existing literature.<\/jats:p>","DOI":"10.1038\/s41598-020-73183-0","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T10:03:01Z","timestamp":1601460181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis"],"prefix":"10.1038","volume":"10","author":[{"given":"Maria Chiara","family":"Ditto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Priora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Lisa","family":"Peroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fusaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"73183_CR1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/d41573-019-00012-z","volume":"18","author":"L Urquhart","year":"2019","unstructured":"Urquhart, L. Top product forecasts for 2019. Nat. Rev. Drug Discov. 18, 91 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"73183_CR2","unstructured":"Terry, M. Drum Roll, Please! Top 10 Bestselling Drugs in the U.S. BioSpace. https:\/\/www.biospace.com\/article\/drumroll-please-top-10-bestselling-drugs-in-the-u-s-\/ (2018)."},{"key":"73183_CR3","doi-asserted-by":"crossref","unstructured":"Philippidis, A. The Top 15 Best-Selling Drugs of 2017. https:\/\/www.genengnews.com\/a-lists\/the-top-15-best-selling-drugs-of-2017\/ (2018).","DOI":"10.1089\/genedge.1.1.05"},{"key":"73183_CR4","unstructured":"Philippidis, A. The Top 15 Best-Selling Drugs of 2016. GEN\u2014Genetic Engineering and Biotechnology News https:\/\/www.genengnews.com\/a-lists\/the-top-15-best-selling-drugs-of-2016\/ (2017)."},{"key":"73183_CR5","unstructured":"Top-Selling, Top-Prescribed Drugs for 2016. https:\/\/www.medscape.com\/viewarticle\/886404 (2017)."},{"key":"73183_CR6","unstructured":"Bartholow, M. Top Drugs of 2015. https:\/\/www.pharmacytimes.com\/publications\/issue\/2016\/july2016\/top-drugs-of-2015 (2016)."},{"key":"73183_CR7","unstructured":"Philippidis, A. The Top 25 Best-Selling Drugs of 2014. https:\/\/www.genengnews.com\/a-lists\/the-top-25-best-selling-drugs-of-2014\/ (2015)."},{"key":"73183_CR8","unstructured":"Brooks, M. Top 100 Most Prescribed, Top-Selling Drugs. https:\/\/www.medscape.com\/viewarticle\/829246 (2014)."},{"key":"73183_CR9","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/jps.24444","volume":"104","author":"L Liu","year":"2015","unstructured":"Liu, L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J. Pharm. Sci. 104, 1866\u20131884 (2015).","journal-title":"J. Pharm. Sci."},{"key":"73183_CR10","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.40388","volume":"70","author":"SL Bridges","year":"2018","unstructured":"Bridges, S. L. et al. The science behind biosimilars: Entering a new era of biologic therapy. Arthritis Rheumatol. Hoboken NJ 70, 334\u2013344 (2018).","journal-title":"Arthritis Rheumatol. Hoboken NJ"},{"key":"73183_CR11","unstructured":"Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf\u00a0EMEA\/CHMP\/BMWP\/42832\/2005 Rev1\u00a0(2014)."},{"key":"73183_CR12","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","volume":"76","author":"S Cohen","year":"2017","unstructured":"Cohen, S. et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study. Ann. Rheum. Dis. 76, 1679\u20131687 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR13","first-page":"834","volume":"76","author":"S Cohen","year":"2017","unstructured":"Cohen, S. et al. SAT0171 Abp 501 biosmilar to adalimumab: Final safety, immunogenicity, and efficacy results from an open-label extension study. Ann. Rheum. Dis. 76, 834\u2013835 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jaad.2016.12.014","volume":"76","author":"K Papp","year":"2017","unstructured":"Papp, K. et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J. Am. Acad. Dermatol. 76, 1093\u20131102 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"73183_CR15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/jcpt.12583","volume":"42","author":"D Shin","year":"2017","unstructured":"Shin, D., Lee, Y., Kim, H., K\u00f6rnicke, T. & Fuhr, R. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. J. Clin. Pharm. Ther. 42, 672\u2013678 (2017).","journal-title":"J. Clin. Pharm. Ther."},{"key":"73183_CR16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/annrheumdis-2015-207588","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery, P. et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann. Rheum. Dis. 76, 51\u201357 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR17","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/bjd.15152","volume":"176","author":"CEM Griffiths","year":"2017","unstructured":"Griffiths, C. E. M. et al. The EGALITY study: A confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br. J. Dermatol. 176, 928\u2013938 (2017).","journal-title":"Br. J. Dermatol."},{"key":"73183_CR18","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park, W. et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study. Ann. Rheum. Dis. 72, 1605\u20131612 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","volume":"76","author":"W Park","year":"2017","unstructured":"Park, W. et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann. Rheum. Dis. 76, 346\u2013354 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR20","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo, D. H. et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study. Ann. Rheum. Dis. 72, 1613\u20131620 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR21","unstructured":"FDA. Biosimilars. https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/biosimilars.FDA\/drugs\/therapeutic-biologics-applications-bla\/biosimilars (2019)."},{"key":"73183_CR22","first-page":"177","volume":"42","author":"BG Feagan","year":"2014","unstructured":"Feagan, B. G. et al. The challenge of indication extrapolation for infliximab biosimilars. Biol. J. Int. Assoc. Biol. Stand. 42, 177\u2013183 (2014).","journal-title":"Biol. J. Int. Assoc. Biol. Stand."},{"key":"73183_CR23","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","volume":"75","author":"T D\u00f6rner","year":"2016","unstructured":"D\u00f6rner, T. et al. The changing landscape of biosimilars in rheumatology. Ann. Rheum. Dis. 75, 974\u2013982 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR24","unstructured":"FDA. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product (2019)."},{"key":"73183_CR25","unstructured":"Information and Submission Requirements for Biosimilar Biologic Drugs seb-pbu-2016-eng.pdf. https:\/\/www.canada.ca\/content\/dam\/hc-sc\/migration\/hc-sc\/dhp-mps\/alt_formats\/pdf\/brgtherap\/applic-demande\/guides\/seb-pbu\/seb-pbu-2016-eng.pdf (2017)."},{"key":"73183_CR26","doi-asserted-by":"crossref","unstructured":"Klein, A. V., Wang, J. & Bedford, P. Subsequent entry biologics (biosimilars) in Canada: approaches to interchangeability and the extrapolation of indications and uses\u2014GaBI Journal. https:\/\/gabi-journal.net\/subsequent-entry-biologics-biosimilars-in-canada-approaches-to-interchangeability-and-the-extrapolation-of-indications-and-uses.html (2014).","DOI":"10.5639\/gabij.2014.0303.033"},{"key":"73183_CR27","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/S1470-2045(14)71220-3","volume":"16","author":"S Nagai","year":"2015","unstructured":"Nagai, S., Yanagihara, R. & Kishioka, Y. Japanese regulatory authority\u2019s perspective on biosimilars. Lancet Oncol. 16, e101 (2015).","journal-title":"Lancet Oncol."},{"key":"73183_CR28","unstructured":"UKMi. Is it safe to switch to a biosimilar medicine? https:\/\/www.sps.nhs.uk\/wp-content\/uploads\/2018\/02\/UKMi_QA-Biosimilars-switching_Aug-2017_FINAL.pdf (2017)."},{"key":"73183_CR29","unstructured":"NHS England. Commissioning framework for biological medicines (including biosimilar medicines). https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2017\/09\/biosimilar-medicines-commissioning-framework.pdf (2017)."},{"key":"73183_CR30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3748\/wjg.v23.i2.197","volume":"23","author":"S Deiana","year":"2017","unstructured":"Deiana, S., Gabbani, T. & Annese, V. Biosimilars in inflammatory bowel disease: A review of post-marketing experience. World J. Gastroenterol. 23, 197\u2013203 (2017).","journal-title":"World J. Gastroenterol."},{"key":"73183_CR31","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/annrheumdis-2015-207738","volume":"75","author":"P Putrik","year":"2016","unstructured":"Putrik, P. et al. In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: Results from the cross-sectional COMORA study. Ann. Rheum. Dis. 75, 715\u2013720 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik, P. et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann. Rheum. Dis. 73, 198\u2013206 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR33","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1136\/annrheumdis-2013-203819","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik, P. et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country\u2019s wealth?. Ann. Rheum. Dis. 73, 2010\u20132021 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR34","unstructured":"NHS England. Commissioning framework for biological medicines biosimilar-medicines-regulation.pdf. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2017\/09\/biosimilar-medicines-commissioning-framework.pdf (2017)."},{"issue":"Suppl 1","key":"73183_CR35","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/s10198-014-0592-6","volume":"15","author":"M P\u00e9ntek","year":"2014","unstructured":"P\u00e9ntek, M. et al. Biological therapy in inflammatory rheumatic diseases: Issues in Central and Eastern European countries. Eur. J. Health Econ. HEPAC Health Econ. Prev. Care 15(Suppl 1), S35\u2013S43 (2014).","journal-title":"Eur. J. Health Econ. HEPAC Health Econ. Prev. Care"},{"key":"73183_CR36","unstructured":"IMS. The Impact of Biosimilar Competition in Europe. https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2017\/05\/IMS-Biosimilar-2017_V9.pdf (2017)."},{"key":"73183_CR37","unstructured":"Roediger, A., Freischem, B. & Reiland, J.-B. What pricing and reimbursement policies to use for off-patent biologicals in Europe?\u2014results from the second EBE biological medicines policy survey\u2014GaBI Journal. https:\/\/gabi-journal.net\/what-pricing-and-reimbursement-policies-to-use-for-off-patent-biologicals-in-europe-results-from-the-second-ebe-biological-medicines-policy-survey.html (2017)."},{"key":"73183_CR38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","volume":"76","author":"DH Yoo","year":"2017","unstructured":"Yoo, D. H. et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann. Rheum. Dis. 76, 355\u2013363 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR39","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2017-211741","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen, J. S. et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: Results of a randomised, double-blind, phase III transition study. Ann. Rheum. Dis. 77, 234\u2013240 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR40","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1136\/annrheumdis-2017-211591","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery, P. et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann. Rheum. Dis. 76, 1986\u20131991 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR41","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/art.40444","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt, M. E. et al. Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: Fifty-two-week phase III randomized study results. Arthritis Rheumatol. Hoboken NJ 70, 832\u2013840 (2018).","journal-title":"Arthritis Rheumatol. Hoboken NJ"},{"key":"73183_CR42","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen, K. K. et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial. Lancet Lond. Engl. 389, 2304\u20132316 (2017).","journal-title":"Lancet Lond. Engl."},{"key":"73183_CR43","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","volume":"76","author":"B Glintborg","year":"2017","unstructured":"Glintborg, B. et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann. Rheum. Dis. 76, 1426\u20131431 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR44","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/annrheumdis-2016-210742","volume":"76","author":"B Glintborg","year":"2017","unstructured":"Glintborg, B. et al. FRI0190 Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. Results from the danbio registry. Ann. Rheum. Dis. 76, 553\u2013554 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR45","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.semarthrit.2017.10.002","volume":"47","author":"J Avouac","year":"2018","unstructured":"Avouac, J. et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. Semin. Arthritis Rheum. 47, 741\u2013748 (2018).","journal-title":"Semin. Arthritis Rheum."},{"key":"73183_CR46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/art.40324","volume":"70","author":"L Tweehuysen","year":"2018","unstructured":"Tweehuysen, L. et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. Hoboken NJ 70, 60\u201368 (2018).","journal-title":"Arthritis Rheumatol. Hoboken NJ"},{"key":"73183_CR47","first-page":"459","volume":"109","author":"W H\u00e4user","year":"2012","unstructured":"H\u00e4user, W., Hansen, E. & Enck, P. Nocebo phenomena in medicine: Their relevance in everyday clinical practice. Dtsch. Arzteblatt Int. 109, 459\u2013465 (2012).","journal-title":"Dtsch. Arzteblatt Int."},{"key":"73183_CR48","first-page":"27","volume":"32","author":"RA McKinnon","year":"2018","unstructured":"McKinnon, R. A. et al. Biosimilarity and interchangeability: Principles and evidence: A systematic review. BioDrugs Clin. Immunother. Biopharm. Gene Ther. 32, 27\u201352 (2018).","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"73183_CR49","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40265-018-0881-y","volume":"78","author":"HP Cohen","year":"2018","unstructured":"Cohen, H. P. et al. Switching reference medicines to biosimilars: A systematic literature review of clinical outcomes. Drugs 78, 463\u2013478 (2018).","journal-title":"Drugs"},{"key":"73183_CR50","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/annrheumdis-2018-213474","volume":"78","author":"B Glintborg","year":"2019","unstructured":"Glintborg, B. et al. To switch or not to switch: Results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann. Rheum. Dis. 78, 192\u2013200 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR51","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","volume":"76","author":"J-Y Choe","year":"2017","unstructured":"Choe, J.-Y. et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann. Rheum. Dis. 76, 58\u201364 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR52","unstructured":"AIFA. Secondo Position Paper AIFA sui Farmaci Biosimilari. https:\/\/www.aifa.gov.it\/sites\/default\/files\/pp_biosimilari_27.03.2018.pdf (2018).\u00a0"},{"key":"73183_CR53","unstructured":"Regione Piemonte. Farmaci biosimilari. https:\/\/www.regione.piemonte.it\/web\/sites\/default\/files\/media\/documenti\/2019-03\/farmaci_biosimilari_linee_indirizzo2.docx.pdf (2017)."},{"key":"73183_CR54","unstructured":"Ursula, A. Biosimilars\u2014Position Paper Updating position statement from the European League Against Rheumatism (EULAR) Standing Committee of People with Arthritis\/Rheumatism in Europe (PARE) August 2018. 7."},{"key":"73183_CR55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","volume":"77","author":"J Kay","year":"2018","unstructured":"Kay, J. et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann. Rheum. Dis. 77, 165\u2013174 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR56","unstructured":"PMDA. Guideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics. https:\/\/www.pmda.go.jp\/files\/000153851.pdf (2009)."},{"issue":"Suppl 1","key":"73183_CR57","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1586\/1744666X.2015.1090313","volume":"11","author":"L Gul\u00e1csi","year":"2015","unstructured":"Gul\u00e1csi, L. et al. Biosimilars for the management of rheumatoid arthritis: Economic considerations. Expert Rev. Clin. Immunol. 11(Suppl 1), S43-52 (2015).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"73183_CR58","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/0929867324666170406112304","volume":"26","author":"L Gulacsi","year":"2019","unstructured":"Gulacsi, L. et al. Biosimilars for the management of inflammatory bowel diseases: Economic considerations. Curr. Med. Chem. 26, 259\u2013269 (2019).","journal-title":"Curr. Med. Chem."},{"key":"73183_CR59","doi-asserted-by":"crossref","unstructured":"La Noce, A. & Marcin, E. Switching from reference to biosimilar products: An overview of the European approach and real-world experience so far. Eur. Med. J. https:\/\/www.emjreviews.com\/rheumatology\/article\/switching-from-reference-to-biosimilar-products-an-overview-of-the-european-approach-and-real-world-experience-so-far\/ (2018).","DOI":"10.33590\/emj\/10313082"},{"key":"73183_CR60","doi-asserted-by":"crossref","first-page":"1272308","DOI":"10.1080\/20016689.2016.1272308","volume":"5","author":"C R\u00e9muzat","year":"2017","unstructured":"R\u00e9muzat, C. et al. Key drivers for market penetration of biosimilars in Europe. J. Mark. Access Health Policy 5, 1272308 (2017).","journal-title":"J. Mark. Access Health Policy"},{"key":"73183_CR61","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1136\/annrheumdis-2018-214757","volume":"79","author":"F Cantini","year":"2020","unstructured":"Cantini, F. & Benucci, M. Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: Possible fallout on non-medical switching. Ann. Rheum. Dis. 79, e13 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"73183_CR62","unstructured":"Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry. 23 (2019)."},{"key":"73183_CR63","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/14712598.2016.1198765","volume":"16","author":"S Gentileschi","year":"2016","unstructured":"Gentileschi, S. et al. Switch from infliximab to infliximab biosimilar: Efficacy and safety in a cohort of patients with different rheumatic diseases. Expert Opin. Biol. Ther. 16, 1311\u20131312 (2016).","journal-title":"Expert Opin. Biol. Ther."},{"key":"73183_CR64","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1517\/14712598.2015.1103733","volume":"15","author":"E Nikiphorou","year":"2015","unstructured":"Nikiphorou, E. et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin. Biol. Ther. 15, 1677\u20131683 (2015).","journal-title":"Expert Opin. Biol. Ther."},{"key":"73183_CR65","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1080\/03007995.2018.1441144","volume":"34","author":"C Codreanu","year":"2018","unstructured":"Codreanu, C., \u0160\u00edrov\u00e1, K., Jaro\u0161ov\u00e1, K. & Batalov, A. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis. Curr. Med. Res. Opin. 34, 1763\u20131769 (2018).","journal-title":"Curr. Med. Res. Opin."},{"key":"73183_CR66","first-page":"29","volume":"9","author":"A Abdalla","year":"2017","unstructured":"Abdalla, A. et al. Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product. Open Access Rheumatol. Res. Rev. 9, 29\u201335 (2017).","journal-title":"Open Access Rheumatol. Res. Rev."},{"key":"#cr-split#-73183_CR67.1","doi-asserted-by":"crossref","unstructured":"Batticciotto, A. et al. Safety and efficacy of switching from originator to CT-P13 infliximab biosimilar in patients affected by spondyloarthritis. A 6-month observational study. Arthritis Rheumatol. 2016","DOI":"10.1136\/annrheumdis-2016-eular.5115"},{"key":"#cr-split#-73183_CR67.2","unstructured":"68 (suppl 10). https:\/\/acrabstracts.org\/abstract\/safety-and-efficacy-of-switching-from-originator-to-ct-p13-infliximab-biosimilar-in-patients-affected-by-spondyloarthritis-a-6-month-observational-study\/ (2016)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73183-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73183-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73183-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T18:53:23Z","timestamp":1696791203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73183-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73183"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73183-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"assertion":[{"value":"30 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16178"}}